<DOC>
	<DOCNO>NCT00725400</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , Cetuximab , target tumor cell either kill deliver tumor-killing substance without harm normal cells.This anti-cancer drug already approve FDA use patient Colorectal Cancer . Cetuximab block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation Therapy use high-energy x-ray kill tumor cell cause less damage normal tissue . Giving drug Cetuximab together Radiation Therapy may kill tumor cell . Surgery common treatment Colorectal Cancer remove tumor , well small margin surround normal tissue possibly nearby lymph node . Surgery usually use conjunction conventional treatment Radiation Therapy . Radiation Therapy surgery may make tumor small reduce amount normal tissue need remove . Radiation Therapy surgery may kill tumor cell remain surgery . Screening test Fecal Occult Blood Test ( FOBT ) Colonoscopy do . Tumor marker Colorectal Carcinoma Carcinoembryonic antigen ( CAE ) CA 19-9 ass response tumor marker Carcinoembryonic antigen ( CAE ) CA 19-9 use periodically Colonoscopy do . Colorectal Cancer Surgery Colon resection ( Colectomy ) , Rectum resection ( Proctectomy ) , Colostomy , Radiofrequency ablation . PURPOSE : Determine tumor response rate treat Cetuximab Radiation Therapy Vs Surgery Radiation Therapy patient Colorectal Cancer stage II IV</brief_summary>
	<brief_title>Comparative Study Cetuximab Radiation Vs Surgery Before After Radiation Patients With Colorectal Carcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary : - Determine response rate patient Colorectal Cancer treat Cetuximab Radiation Therapy Vs Surgery Radiation Therapy . Secondary : - To determine progression-free survival overall survival patient treat regimen . - Compare treatment compliance patient treat regimen . - Compare safety regimens patient . OUTLINE : This Open-label , Controlled , Multicenter study . Patients assign two different Arms . Arm I : Patients receive Cetuximab Radiation Therapy . Patients receive dose Cetuximab Intravenous ( IV ) . The initial dose 400 mg/m2 administer 120-minute intravenous infusion ( maximum infusion rate 10 mg/min ) weekly dose 250 mg/m2 infuse 60 minute ( maximum infusion rate 10 mg/min ) disease progression unacceptable toxicity . Radiation treatment Colorectal Cancer Intensity Modulated Radiation Therapy ( IMRT ) . IMRT deliver radiation directly tumor modulates intensity radiation laser accuracy . Arm II : Patients undergo surgery Radiation Therapy . Colorectal Cancer Surgery Colon resection ( Colectomy ) , Rectum resection ( Proctectomy ) , Colostomy , Radiofrequency ablation . Radiation treatment Colorectal Cancer Intensity Modulated Radiation Therapy ( IMRT ) . IMRT deliver radiation directly tumor modulates intensity radiation laser accuracy . PROJECTED ACCRUAL : Approximately 450 patient accrue study within 18 24 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients stage II IV Colorectal Cancer Patients must 40 year old Patients may race either gender Signed Informed Consent Patient characteristic : Age : 40 year old Sex : Both Performance status : Not specify Life expectancy : Not specify Hematopoietic : Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL No history significant bleeding event within past 6 month Hepatic : Bilirubin ≤ 1.5 mg/dL Albumin ≥ 2.5 g/dL Renal : Creatinine ≤ 1.5 time upper limit normal Protein &lt; 1+ urinalysis Protein &lt; 1 g 24hour urine collection Cardiovascular : No conduction defect heart No congestive heart failure No myocardial infarction within last 6 month No cerebrovascular accident No uncontrolled hypertension No clinically significant peripheral artery disease Pulmonary : No pulmonary embolism No interstitial pneumonia No extensive symptomatic interstitial fibrosis lung Neurologic : No uncontrolled seizure disorder No active neurological disease Other : Not pregnant nursing Negative pregnancy test Age 40 year Brain nervous system metastases Any current mental illness Hemoglobin le 9.0 g/dl CBC result normal range Patients Hepatitis B C HIV positive Pregnant nursing patient eligible entry study Hepatic abnormality AST/ALT &gt; 4 fold</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Surgery</keyword>
	<keyword>Radiation</keyword>
</DOC>